Dogwood Therapeutics Reports Third Quarter 2025 Financial Results
Provided By GlobeNewswire
Last update: Nov 6, 2025
- Enrollment to date of 100 patients, with 80 patients completing treatment in the ongoing Halneuron® Phase 2b trial, prespecified interim analysis remains on track for Q4 2025 release -
Read more at globenewswire.com6.34
+0.39 (+6.55%)
Find more stocks in the Stock Screener
DWTX Latest News and Analysis
17 days ago - By: Chartmill
